Physician profile
Ellen R Jacobson
NPI 1962456772
$3,452.41
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $144 · 2021: $395 · 2022: $631 · 2023: $1,150 · 2024: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.46 |
| Education | $282.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.18 | 2019-2024 | |
| Galderma Laboratories, L.P. | $440.90 | 2019-2024 | Aklief |
| Janssen Biotech, INC. | $363.29 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $340.53 | 2019-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $197.55 | 2023-2024 | Sotyktu |
| Organogenesis INC. | $173.06 | 2021-2022 | |
| Lilly USA, LLC | $161.24 | 2022-2024 | Olumiant, Taltz, Zepbound |
| Pfizer INC. | $151.91 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $143.84 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $138.63 | 2022-2024 | Odomzo, Blu-U, Ilumya |
| Epi Health, LLC | $110.33 | 2022 | |
| Genzyme Corporation | $87.58 | 2021-2024 | |
| Leo Pharma INC. | $87.31 | 2023-2024 | Adbry |
| Amgen INC. | $78.86 | 2021-2023 | Otezla |
| Biofrontera INC. | $75.47 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.43 | 2019-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.17 | 2023 | Cyltezo |
| Allergan, INC. | $39.54 | 2022 | |
| Dermavant Sciences, INC. | $34.39 | 2024 | Vtama |
| Organon LLC | $33.88 | 2023 | Hadlima |
| Incyte Corporation | $21.79 | 2023 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $18.34 | 2022 | |
| Almirall LLC | $17.98 | 2019 | |
| Journey Medical Corporation | $16.40 | 2022 | |
| Merz North America, INC. | $15.69 | 2019 | |
| Dusa Pharmaceuticals, INC. | $11.41 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.24 | 2019 | |
| Mayne Pharma Commercial LLC | $7.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.